Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mathews John

Psychiatry Terre Haute, IN Medical Doctor

NPI 1174571574 CMS profile 396500

609 E Surgery Center Dr, Terre Haute, IN 47802

Open in the dashboard

General payments

$5,385

272 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mathews John of Terre Haute, IN is reported in the CMS Open Payments database as having received $5,385 across 272 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,061 38
2024 General $1,046 40
2023 General $518 28
2022 General $629 35
2021 General $780 49
2020 General $644 39
2019 General $708 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mathews John
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Mathews John were reported at $1,061. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Mathews John Psychiatry median Middle half National median
2019 $708 $184 $59–$605 $163
2020 $644 $119 $36–$372 $114
2021 $780 $143 $43–$576 $132
2022 $629 $153 $50–$590 $149
2023 $518 $170 $56–$651 $160
2024 $1,046 $179 $57–$673 $164
2025 $1,061 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lundbeck LLC $939 53 payments
  2. Teva Pharmaceuticals USA, Inc. $841 34 payments
  3. Otsuka America Pharmaceutical, Inc. $616 23 payments
  4. Janssen Pharmaceuticals, Inc $341 17 payments
  5. Alkermes, Inc. $293 16 payments
  6. AbbVie, Inc. $275 20 payments
  7. Neurocrine Biosciences, Inc. $264 12 payments
  8. Supernus Pharmaceuticals, Inc. $251 4 payments
  9. Ironshore Pharmaceuticals Inc. $208 11 payments
  10. E.R. Squibb & Sons, L.L.C. $199 7 payments
  11. Other $1,158 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,032 267 payments
  2. Education $353 5 payments
Products named General payments · program years 2019–2025
  1. REXULTI Psychiatry $513 17 payments
  2. ABILIFY MAINTENA $504 27 payments
  3. REXULTI Psychiatry $448 26 payments
  4. ARISTADA Cns $293 16 payments
  5. ARISTADA Cns $293 16 payments
  6. VRAYLAR $275 20 payments
  7. SPRAVATO $262 12 payments
  8. ARISTADA Cns $247 14 payments
  9. ARISTADA Cns $247 14 payments
  10. Austedo XR $219 11 payments
  11. Other $3,144 174 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 78 drugs

Part D claims

5,201

Median for Psychiatry: 574

Drug cost

$1,092,935

Median for Psychiatry: $27,624

Branded share of claims

25.9%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 63 $458,556
Vraylar Cariprazine Hcl Brand 82 $129,109
Invega Sustenna Paliperidone Palmitate Brand 45 $116,140
Fanapt Iloperidone Brand 46 $61,220
Caplyta Lumateperone Tosylate Brand 36 $58,786
Lybalvi Olanzapine/Samidorphan Malate Brand 27 $41,987
Auvelity Dextromethorphan Hbr/Bupropion Brand 26 $30,898
Rexulti Brexpiprazole Brand 18 $26,970
Lurasidone Hcl Generic 32 $15,841
Trintellix Vortioxetine Hydrobromide Brand 32 $15,584

The 10 drugs with the highest cost, of 78 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$45,966

Medicare's payments for the services billed

Medicare patients

113

Average age 60

Services billed

630

65 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Depression 58%
Arthritis 40%
Diabetes 35%
Ischemic heart disease 22%
COPD 22%
Chronic kidney disease 19%
Alzheimer's or dementia 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $118
  • Lundbeck LLC $63
$181 18 —
INGREZZA
  • Neurocrine Biosciences, Inc. $95
$95 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $94
$94 63 —
Qelbree
  • Supernus Pharmaceuticals, Inc. $77
$77 12 —
ABILIFY ASIMTUFII
  • Lundbeck LLC $72
$72 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

272 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record